Can brain amyloid reduction be used as a surrogate biomarker of clinical benefit? This is a hotly debated question in the field (see Dec 2024 discussion). A recent post hoc analysis of Phase 3 ...

Biogen and Denali yesterday announced they will stop development of the LRRK2 kinase inhibitor DNL151 for sporadic Parkinson’s disease. Top-line data from the LUMA Phase 2b trial indicated that the ...

The family tree of tau filament folds continues to sprout new branches. With them come new questions. At the Tau Global Conference, held May 14-15 in Washington, D.C., scientists grappled with the ...

Are efforts to target tau finally starting to pay off? Just a little, maybe? The Tau Global Conference, held in Washington, D.C., May 14 to 15, showcased recent progress in basic science, biomarkers, ...

Can PI-2620 track progressive supranuclear palsy (PSP)? Scientists led by Matthias Brendel at Ludwig Maximilian University, Munich, have found that the tracer captures tau accumulation in several ...

Comments For TDP-43 Aggregates, Breaking Up Is No Longer Hard to Do 13 May 2026 ...

Lu AF87908 is a humanized mouse IgG1 monoclonal antibody to phosphorylated tau protein. It was generated by immunization of mice with a tau peptide spanning residues 386-408 and phosphorylated at ...

At the Tau Global conference, speakers showcased progress in an antisense oligonucleotide and a small-molecule p75 modulator. Other strategies also look promising.

03 June 2026 DOWNLOAD TO YOUR CALENDAR London, U.K. View Conference Website ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...

In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...